| Follow Us: Facebook Twitter Youtube RSS Feed

In The News

Good news for bad guts

A local biotech startup, Encycle Therapeutics, is the recipient of a generous grant to further research its development of an oral treatment for inflammatory bowel disease, or IBD--the first of its kind.

Encycle was founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, who are working from a $4 million public-private funding partnership with Merck Canada. 

As Dr. Raphael Hofstein, president and CEO of MaRS Innovation, told Drug Discovery and Development: "Encycle Therapeutics has spent the last 18 months demonstrating the significant potential of its innovative macrocyle chemistry platform to generate small-cell permeable systems. This achievement has resulted in multiple partnership opportunities, affirming its position as one of Canada's emerging biotechnology companies to watch."

Read more here.
Source: Drug Discovery and Development magazine
Signup for Email Alerts
Signup for Email Alerts

Related Content